BIRC5 and ovarian carcinoma: The study examined 111 ovarian tissue samples for survivin expression using reverse transcription-polymerase chain reaction, quantified the expression using quantitative real-time PCR and found that survivin was highly expressed in ovarian carcinoma (73%) compared to benign (47%) and borderline (19%) ovarian tumors (p < 0.001).